Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 30 01:12PM ET
29.30
Dollar change
+13.24
Percentage change
82.44
%
IndexRUT P/E- EPS (ttm)-0.30 Insider Own2.57% Shs Outstand266.26M Perf Week81.54%
Market Cap7.80B Forward P/E81.31 EPS next Y0.36 Insider Trans-38.25% Shs Float259.43M Perf Month97.17%
Income-73.52M PEG- EPS next Q0.12 Inst Own91.24% Short Float / Ratio12.59% / 6.74 Perf Quarter84.97%
Sales287.61M P/S27.12 EPS this Y107.44% Inst Trans1.68% Short Interest32.66M Perf Half Y106.77%
Book/sh2.11 P/B13.87 EPS next Y450.37% ROA-12.45% Target Price23.29 Perf Year484.83%
Cash/sh2.27 P/C12.88 EPS next 5Y- ROE-19.88% 52W Range3.61 - 20.69 Perf YTD490.73%
Dividend- P/FCF- EPS past 5Y2.15% ROI-11.17% 52W High41.61% Beta0.82
Dividend %- Quick Ratio5.65 Sales past 5Y13.91% Gross Margin98.51% 52W Low712.76% ATR1.72
Employees277 Current Ratio5.70 Sales Q/Q637.72% Oper. Margin-27.88% RSI (14)87.59 Volatility4.53% 5.63%
OptionableYes Debt/Eq0.20 EPS Q/Q134.85% Profit Margin-25.56% Rel Volume17.39 Prev Close16.06
ShortableYes LT Debt/Eq0.17 EarningsNov 02 BMO Payout- Avg Volume4.84M Price29.30
Recom1.56 SMA2087.60% SMA5093.98% SMA200130.24% Volume49,767,585 Change82.44%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Initiated Goldman Neutral $17
Nov-09-23Initiated Deutsche Bank Buy $25
Oct-06-23Initiated Oppenheimer Perform $16
May-03-23Upgrade Piper Sandler Neutral → Overweight $6 → $16
Nov-21-22Initiated Truist Buy $10
Sep-09-22Initiated Barclays Overweight $8
Mar-21-22Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $6
Feb-11-22Initiated BMO Capital Markets Outperform $18
Dec-01-21Upgrade Jefferies Hold → Buy $7 → $12
Oct-26-20Resumed H.C. Wainwright Buy $11
Today 11:49AM
10:40AM
10:38AM
10:37AM
10:32AM
10:12AM Loading…
10:12AM
09:44AM
09:30AM
08:19AM
08:18AM
07:51AM
07:45AM
07:41AM
07:33AM
07:30AM
01:47PM Loading…
Nov-27-23 01:47PM
Nov-22-23 09:55AM
08:57AM
Nov-18-23 09:03AM
Nov-15-23 09:35AM
09:30AM
Nov-06-23 09:55AM
Nov-04-23 12:16PM
Nov-03-23 04:22PM
12:18PM
Nov-02-23 04:30PM
07:54AM
07:50AM
06:47AM
06:30AM
04:30PM Loading…
Nov-01-23 04:30PM
Oct-31-23 10:01AM
Oct-30-23 02:07PM
Oct-27-23 06:30AM
Oct-26-23 10:02AM
Oct-25-23 08:34AM
Oct-24-23 01:22AM
Oct-23-23 05:59PM
08:30AM
Oct-20-23 01:22PM
09:00AM
Oct-19-23 04:01PM
Oct-06-23 09:42AM
Oct-04-23 09:55AM
Sep-29-23 05:00PM
Sep-28-23 07:00AM
Sep-18-23 05:09PM
05:00PM
06:30AM
Sep-14-23 02:02PM
Sep-07-23 07:08AM
Sep-05-23 04:30PM
Aug-28-23 06:30AM
Aug-21-23 04:20PM
Aug-17-23 06:40AM
Aug-01-23 04:30PM
10:09AM
10:00AM
09:25AM
02:16AM
Jul-31-23 07:55AM
06:43AM
06:35AM
06:30AM
Jul-27-23 04:30PM
Jul-26-23 06:58AM
Jul-25-23 10:01AM
Jul-24-23 10:00AM
06:30AM
Jul-18-23 09:40AM
Jul-17-23 04:01PM
09:35AM
Jul-13-23 10:48AM
Jul-06-23 04:43PM
Jul-03-23 04:30PM
Jul-02-23 02:11PM
Jun-27-23 09:50AM
Jun-09-23 01:32PM
05:33AM
03:00AM
Jun-08-23 11:31AM
Jun-07-23 11:30AM
Jun-06-23 06:50AM
06:31AM
Jun-05-23 04:06PM
Jun-04-23 08:00AM
Jun-02-23 11:31AM
Jun-01-23 04:30PM
May-24-23 04:30PM
May-22-23 06:59AM
May-19-23 11:09AM
10:00AM
May-12-23 12:08PM
May-11-23 09:58AM
09:55AM
May-09-23 04:01PM
06:30AM
May-04-23 07:45PM
02:30PM
May-03-23 05:39PM
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERNov 17Option Exercise7.6178,223595,441115,189Nov 17 07:52 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERNov 17Sale16.0578,2231,255,47936,966Nov 17 07:52 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERNov 16Option Exercise5.534,10022,66541,066Nov 17 07:52 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERNov 16Sale16.014,10065,64136,966Nov 17 07:52 PM
Wingrove TheresaSVP OF REGULATORY AFFAIRSNov 15Option Exercise4.55166,725758,599169,536Nov 17 07:53 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERNov 15Option Exercise5.4826,286144,00863,252Nov 17 07:52 PM
Wingrove TheresaSVP OF REGULATORY AFFAIRSNov 15Sale15.85166,7252,642,5912,811Nov 17 07:53 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERNov 15Sale16.0126,286420,83936,966Nov 17 07:52 PM
Wingrove TheresaSVP OF REGULATORY AFFAIRSNov 07Option Exercise10.6519,517207,85622,328Nov 08 05:56 PM
Wallace Richard JohnDirectorNov 07Option Exercise14.7010,000147,00010,000Nov 08 05:53 PM
Wingrove TheresaSVP OF REGULATORY AFFAIRSNov 07Sale16.6619,517325,1532,811Nov 08 05:56 PM
Lentini ReneeVP & PRIN ACCTG OFFICERNov 06Option Exercise7.83120,528943,442219,545Nov 08 05:55 PM
Lentini ReneeVP & PRIN ACCTG OFFICERNov 06Sale15.29219,5453,356,8430Nov 08 05:55 PM
Goldberg Mark AlanDirectorOct 30Option Exercise14.7010,000147,00070,151Nov 01 05:59 PM
Wingrove TheresaSVP OF REGULATORY AFFAIRSOct 16Option Exercise4.55192,004873,618194,815Oct 18 04:25 PM
Wingrove TheresaSVP OF REGULATORY AFFAIRSOct 16Sale14.40192,0042,764,8582,811Oct 18 04:25 PM
MITCHELL DEAN JDirectorSep 22Option Exercise14.7010,000147,000152,667Sep 26 04:08 PM
Wingrove TheresaSVP OF REGULATORY AFFAIRSSep 15Option Exercise3.65108,668397,064194,824Sep 19 05:27 PM
Wingrove TheresaSVP OF REGULATORY AFFAIRSSep 15Sale15.44192,0132,964,6812,811Sep 19 05:27 PM
Peterson KristineDirectorSep 13Option Exercise14.7010,000147,00010,000Sep 14 05:31 PM
MCCLUSKI STEPHEN CDirectorSep 13Option Exercise14.7010,000147,00010,000Sep 14 05:30 PM
Lentini ReneePRIN. FIN & ACCTG. OFF.Sep 12Option Exercise3.9725,14199,80899,017Sep 14 05:29 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSep 08Option Exercise7.6926,006199,98636,966Sep 11 04:08 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERAug 09Option Exercise4.92100,210493,033111,170Aug 11 05:02 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERAug 09Sale14.20100,2101,422,98210,960Aug 11 05:02 PM
Enyedy Mark JCHIEF EXECUTIVE OFFICERAug 04Option Exercise5.341,104,2185,901,7601,545,667Aug 04 07:32 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERAug 04Option Exercise4.9280,326395,20491,286Aug 04 07:33 PM
Enyedy Mark JCHIEF EXECUTIVE OFFICERAug 04Sale16.96992,39716,831,053553,270Aug 04 07:32 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERAug 04Sale17.0580,3261,369,55810,960Aug 04 07:33 PM
Enyedy Mark JCHIEF EXECUTIVE OFFICERAug 03Option Exercise4.551,020,0004,642,9321,461,449Aug 04 07:32 PM
Lentini ReneePRIN. FIN & ACCTG. OFF.Aug 03Option Exercise2.4551,033124,90773,876Aug 04 07:28 PM
Enyedy Mark JCHIEF EXECUTIVE OFFICERAug 03Sale16.611,020,00016,942,200441,449Aug 04 07:32 PM
Enyedy Mark JCHIEF EXECUTIVE OFFICERAug 02Option Exercise4.55995,1574,527,9641,436,606Aug 04 07:32 PM
Lentini ReneePRIN. FIN & ACCTG. OFF.Aug 02Option Exercise4.57148,277677,777171,120Aug 04 07:28 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERAug 02Option Exercise4.924,25520,93515,215Aug 04 07:33 PM
Enyedy Mark JCHIEF EXECUTIVE OFFICERAug 02Sale17.46995,15717,371,535441,449Aug 04 07:32 PM
Lentini ReneePRIN. FIN & ACCTG. OFF.Aug 02Sale17.55148,2772,602,26122,843Aug 04 07:28 PM
Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERAug 02Sale18.124,25577,10110,960Aug 04 07:33 PM